Literature DB >> 8795804

Melatonin and insomnia.

C M Ellis1, G Lemmens, J D Parkes.   

Abstract

The hypnotic action of melatonin 5 mg p.o. was explored in 15 subjects with psychophysiological insomnia in a double-blind controlled self-report questionnaire study. Melatonin or placebo was taken at 20.00 hours for a 1-week period in random order. Effects on sleep and wakefulness were monitored by visual analogue scale and structured interview. Bedtime, sleep onset time, estimated total sleep and wake time, as well as self-rated sleep quality, were not altered by melatonin, and estimates of next-day function did not change. The period of melatonin, treatment was retrospectively correctly identified by 8 of 15 subjects. Despite unchanged ratings of night sleep quality on the last night of each treatment, 7 of 15 subjects reported that sleep had subjectively improved to a minor extent in the week of active treatment. Side-effects attributed to melatonin included headache and an odd taste in the mouth. These data indicate that melatonin is probably of no clinical value in the management of psychophysiological insomnia.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8795804     DOI: 10.1046/j.1365-2869.1996.00003.x

Source DB:  PubMed          Journal:  J Sleep Res        ISSN: 0962-1105            Impact factor:   3.981


  12 in total

1.  Sleep in Autism Spectrum Disorders.

Authors:  Olivia J Veatch; Angela C Maxwell-Horn; Beth A Malow
Journal:  Curr Sleep Med Rep       Date:  2015-06

2.  How to get medical information from the Internet.

Authors:  R Kiley
Journal:  J R Soc Med       Date:  1997-09       Impact factor: 5.344

Review 3.  Melatonin therapy for REM sleep behavior disorder: a critical review of evidence.

Authors:  Ian R McGrane; Jonathan G Leung; Erik K St Louis; Bradley F Boeve
Journal:  Sleep Med       Date:  2014-10-13       Impact factor: 3.492

Review 4.  Sleep disorders in the elderly.

Authors:  R Asplund
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

Review 5.  Adverse Events Associated with Melatonin for the Treatment of Primary or Secondary Sleep Disorders: A Systematic Review.

Authors:  Frank M C Besag; Michael J Vasey; Kim S J Lao; Ian C K Wong
Journal:  CNS Drugs       Date:  2019-12       Impact factor: 5.749

6.  The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis.

Authors:  Nina Buscemi; Ben Vandermeer; Nicola Hooton; Rena Pandya; Lisa Tjosvold; Lisa Hartling; Glen Baker; Terry P Klassen; Sunita Vohra
Journal:  J Gen Intern Med       Date:  2005-12       Impact factor: 5.128

Review 7.  Complementary and alternative therapies for fibromyalgia.

Authors:  L J Crofford; B E Appleton
Journal:  Curr Rheumatol Rep       Date:  2001-04       Impact factor: 4.592

Review 8.  Role of the melatonin system in the control of sleep: therapeutic implications.

Authors:  Seithikurippu R Pandi-Perumal; Venkatramanujan Srinivasan; D Warren Spence; Daniel P Cardinali
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 9.  The relevance of melatonin to sports medicine and science.

Authors:  Greg Atkinson; Barry Drust; Thomas Reilly; Jim Waterhouse
Journal:  Sports Med       Date:  2003       Impact factor: 11.136

10.  Treatment of primary insomnia with melatonin: a double-blind, placebo-controlled, crossover study.

Authors:  Luis G Almeida Montes; Marta P Ontiveros Uribe; José Cortés Sotres; Gerardo Heinze Martin
Journal:  J Psychiatry Neurosci       Date:  2003-05       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.